Pfizer's Florida: A Healthy State program will soon begin to analyze the effectiveness of its high blood pressure and Type
2 diabetes disease education programs.
The Florida Health Literacy Study launch event held at the University of South Florida drew participants (l to r) Barbara
DeBuono, MD, MPH, senior medical director/group leader, public health, Pfizer Pharmaceuticals Group; Judy Genshaft, PhD, president,
University of South Florida; Karen Katen, executive vice-president, Pfizer Inc., president, Pfizer global pharmaceuticals,
and president, Pfizer US pharmaceuticals.
Both efforts aim to increase the health literacy-the ability to read, understand, and act upon healthcare information-of the
state's Medicaid population. According to the National Academy on an Aging Society, those with low health-literacy skills
are less likely to obtain preventive care and more likely to be hospitalized and have poor health outcomes.
"Solving a problem of this complexity requires a better understanding of how medical outcomes are affected by appropriate
patient education and indi- viduals' involvement in their own care," says Karen Katen, president of Pfizer Global Pharmaceuticals.
"Energetic public/private partnerships represent the best opportunity to gather that kind of information."
The University of South Florida College of Public Health, in conjunction with the Agency for Health Care Administration, will
conduct the Florida Health Literacy Study at 28 community centers through June 30, 2003. Researchers will evaluate patients'
class attendance, the effectiveness of interactive educational materials, and the results of behavior modification and disease-management
programs based on changes in patients' control over blood sugar, blood pressure levels, knowledge of those conditions, and
self-care. The study will help gauge the effect of Pfizer's partnership with Florida in educating patients to self-manage
their chronic conditions and reduce the state's healthcare costs.